South Korea vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Immunization, DPT

South Korea
97.0%
in 2024
Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
83.7%
in 2024
South Korea rank
29th
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank
30th

Immunization, DPT over time

  • South Korea
  • Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
20406080100198020022024

How they compare

South Korea currently reports 97.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), a difference of 13.3%.

That makes South Korea's figure about 1.2 times Middle East, North Africa, Afghanistan & Pakistan (excluding high income)'s.

The two have swapped places 2 times across 44 shared years of data; in 1981 it was South Korea ahead.

South Korea ranks 29th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 30th of 193 countries.

South Korea has averaged higher in every one of the 5 decades both report.

Head to head by decade

Decade South Korea Middle East, North Africa, Afghanistan & Pakistan (excluding high income) Difference Ahead
1980s 69.2% 43.5% 25.7% South Korea
1990s 84.7% 68.2% 16.5% South Korea
2000s 94.9% 75.2% 19.7% South Korea
2010s 97.9% 79.6% 18.3% South Korea
2020s 97.8% 82.6% 15.2% South Korea

Averages of every year both report within each decade.

Frequently asked questions

Which has higher immunization, dpt, South Korea or Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
South Korea, at 97.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) as of 2024.
What is the difference in immunization, dpt between South Korea and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
13.3%, with South Korea ahead.
How many years of comparable data are there for South Korea and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
44 years are reported by both, from 1981 to 2024.
How do South Korea and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank globally for immunization, dpt?
South Korea ranks 29th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 30th of 193 countries.
Where does this data come from?
World Health Organization (WHO), published as Immunization, DPT (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

South Korea vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Immunization, DPT. Statizoid, drawing on World Health Organization (WHO). Retrieved 18 September 2026, from https://health.statizoid.com/compare/immunization-dpt-percent-of-children-ages-12-23-months/korea-rep/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/compare/immunization-dpt-percent-of-children-ages-12-23-months/korea-rep/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/">South Korea vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Immunization, DPT</a> — Statizoid

About this data

Indicator
Immunization, DPT (% of children ages 12-23 months)
Unit
% of children ages 12-23 months
Source
World Health Organization (WHO)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
240 places, 10,124 data points, 1980–2024
Last refreshed

Child immunization, DPT, measures the percentage of children ages 12-23 months who received DPT vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.